A Randomized, Partial Blinded, Placebo-Controlled Phase I Safety and Immunogenicity Study in Healthy Subjects of Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant.

Trial Profile

A Randomized, Partial Blinded, Placebo-Controlled Phase I Safety and Immunogenicity Study in Healthy Subjects of Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant.

Suspended
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2015

At a glance

  • Drugs Agatolimod (Primary) ; Escherichia coli vaccine
  • Indications Gram-negative infections
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Oct 2015 Results published in the Vaccine
    • 30 Aug 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 18 Nov 2011 Actual initiation date changed from Oct 2011 to Nov 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top